Methoxy flavonoid compound as medicament for preventing and controlling metabolism complex disease and using method

A technology for methoxyflavonoids and metabolic syndrome, applied in the field of methoxyflavonoids, can solve the problems of low yield, high price, inability to carry out experimental research, etc., to reduce the incidence of complications, prolong the survival period, Reduce the effect of the cardiovascular system

Inactive Publication Date: 2008-09-24
HUAZHONG UNIV OF SCI & TECH
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The content of methoxylated flavonoids in plants is relatively small. So far, there has been no major breakthrough in the extraction process of polymethoxylated flavonoids. The yield is very small and the price is expensive, which makes the overall experimental research impossible.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methoxy flavonoid compound as medicament for preventing and controlling metabolism complex disease and using method
  • Methoxy flavonoid compound as medicament for preventing and controlling metabolism complex disease and using method
  • Methoxy flavonoid compound as medicament for preventing and controlling metabolism complex disease and using method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Sixty male mice were randomly divided into 4 groups, 15 in each group and 5 in each cage. Food and water were given ad libitum, and feed and water consumption was calculated daily. Both the solvent and the drug were intragastrically administered at 10ml / kg body weight once a day. A: normal feed + solvent, B: normal feed + PMQ (50mg / kg / d), C: high-fat feed + solvent, D: high-fat feed + PMQ (50mg / kg / d). lasts for 3 months. The animals were fasted for 12 hours before slaughter, anesthetized with ether, and blood was collected from the orbit to prepare serum. Slaughter animals, carry out relevant parameter measurement, the result is as follows:

[0034] 1. Whether it is normal feed or high-fat feed, there is no significant difference in feed consumption and drinking water between PMQ group and solvent control group. Prompt that the drug does not affect appetite.

[0035] 2. Whether it is normal feed or high-fat feed, the body weight of PMQ group is significantly lower ...

Embodiment 2

[0039]Male SD rats, weighing about 250g, were prepared with 2 kidneys and 1 clip as a model of renal hypertension. After the operation, high-fat diets were fed. After the blood pressure increased significantly, the islet β cells were damaged with alloxan, and the blood sugar increased. . Finally, a metabolic syndrome model (expressed as elevated blood pressure, high blood triglycerides, high blood total cholesterol, and high blood sugar) was formed. One week after islet injury, the animals were divided into a treatment group (PMQ 50 mg / kg / d) and a solvent control group, and administered by intragastric administration. Before administration and every 10 days or longer after administration, blood was collected from the orbit under light ether anesthesia to prepare serum. The result is as follows:

[0040] 1. After modeling, the food intake and water intake of the solvent control group were higher than those of the PMQ group, but their body weight no longer increased or decreas...

Embodiment 3

[0046] Male SD rats, weighing about 250 g, took the thoracic aorta after anesthesia, and prepared arterial ring specimens with a width of about 0.3-0.4 cm. The changes in vascular tension were measured in the isolated organ bath under conditions close to the internal environment. The results are as follows:

[0047] 1. PQM can concentration-dependently resist the degree of vasoconstriction caused by methoxyamine;

[0048] 2. In the vascular specimens pre-contracted with methoxyamine, PQM produced a concentration-dependent relaxation effect. In the specimens without endothelium, the relaxation effect was significantly weakened, but not disappeared. It shows that its vasodilation effect has two components involved in the vascular endothelium-dependent and vascular endothelium-independent components.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a methoxyl flavonoids compound used as a drug for preventing and treating MS (metabolic syndrome) and the usage. As for high-risk MS groups or patients diagnosed with MS, an effective dose of methoxyl flavonoids or compound preparations containing the substances can be adopted for a prevention and/or treatment.

Description

technical field [0001] The present invention relates to methoxyflavonoids (polymethoxylflavonoids) as medicines and usages for preventing and treating MS, especially polymethoxyflavonoids, such as pentamethylquercetin (3,5,7,3',4 '-pentamethoxylflavone, pentamethylquercetin, PMQ). Background technique [0002] MS is composed of multiple metabolic risk factors such as abdominal obesity, hypertension, hyperglycemia, abnormal blood lipid levels and insulin resistance (Dandona P, Circulation.2005; 111:1448-1454.). Globally, the incidence of MS is increasing rapidly, and it is considered to be one of the major threats to human health in the 21st century, and has received great attention from the medical community at home and abroad (Kern PA, Current Opinion in Cardiology 2006; 21: 479-485). [0003] The components of MS have both risk factors and characteristics of the disease, and are mutually causal, interactive, and intricate. At present, it is believed that the etiology of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P3/00
Inventor 金满文杨斐吴晗何婷胡燕
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap